News
Teva and Xenon remain fully committed to the development of TV-45070 for neuropathic pain indications and await the results from the ongoing PHN Phase 2b study, expected in the second half of 2016.
STAINES-UPON-THAMES, United Kingdom and ABINGDON, United Kingdom and BUFFALO, N.Y., Aug. 23, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback